|
|
|
| The Diagnostic Value of Serum OPG BSAP and FGF-23 for Vascular Calcification in Patients Under Hemodialysis |
| SONG Juxiang, XIA Weiqing, WANG Tianzhi, et al |
| The Third Hospital of Shijiazhuang, Hebei Shijiazhuang 050000, China |
|
|
|
|
Abstract Objective: To investigate the diagnostic value of serum Osteoprotegerin (OPG), bone specific alkaline phosphatase (BSAP) and fibroblast growth factor 23 (FGF-23) for vascular calcification (VC) in patients under hemodialysis. Methods: A total of 133 patients under hemodialysis were selected from January 2018 to October 2020, of which 58 patients with VC were in the calcification group and 75 patients without VC were in the non-calcification group. The levels of serum OPG, BSAP and FGF-23 in the two groups were determined by enzyme linked immunosorbent assay (ELISA). The diagnostic values of serum OPG, BSAP and FGF-23 in VC were explored by ROC curve. Results: The levels of serum OPG, BSAP and FGF-23 in the calcification group were higher than those in the non-calcification group (P<0.05). With the aggravation of calcification, the levels of serum OPG, BSAP and FGF-23 were significantly increased (P<0.05). Spearman correlation analysis showed that OPG, BSAP and FGF-23 were positively correlated with VC score of dialysis patients (P<0.05). Logistic regression analysis showed that longer dialysis age and elevated of OPG, BSAP, FGF-23 were risk factors for VC in dialysis patients (P<0.05). The AUC of serum OPG, BSAP and FGF-23 were 0.853, 0.864 and 0.866 respectively. The AUC and specificity of the combined test in VC were significantly higher than that of the single test (P<0.05). Conclusion: The expression of serum OPG, BSAP and FGF-23 is closely related to VC in patients under hemodialysis. The combined detection is of great significance for the diagnosis and evaluation of VC.
|
|
|
|
|
|
[1] 邢玥,贾俊亚,张雅濡,等.不同阶段慢性肾脏病患者血清成纤维细胞生长因子23与血管钙化的相关性[J].中国现代医学杂志,2019,29(14):101~105.
[2] Oikonomaki T,Papasotiriou M,Ntrinias T,et al.The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients:a 1-year follow-up randomized trial [J].Int Urol Nephrol,2019,51(11):2037~2044.
[3] Matsuura T,Abe T,Onoda M,et al.Pelvic artery calcification score Is a marker of vascular calcification in male hemodialysis patients [J].Ther Apher Dial,2018,22(5):509~513.
[4] Khodeir SA,Okda HI,Abdalal HM.Clinical significance of fibroblast growth factor-23 and soluble alpha klotho in different stages of chronic kidney disease [J].Saudi Kidney Dis Transpl,2019,30(1):108~118.
[5] 宋菊香,夏薇青,马辉,等.不同血液净化方式对维持性血液透析患者矿物质及骨代谢状况的影响[J].河北医学,2021,27(1):105~109.
[6] Yan J,Li L,Zhang M,et al.Circulating bone-specific alkaline phosphatase and abdominal aortic calcification in maintenance hemodialysis patients [J].Biomark Med,2018,12(11):1231~1239.
[7] Ganidagli B,Nacar H,Yildiz YS,et al.The relationship between serum osteopontin and FGF 23 levels with valvular calcification in hemodialysis patients [J].Clin Nephrol,2019,91(1):9~16.
[8] Raggi P,Bellasi A,Bushinsky D,et al.Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis:results of a randomized phase 2b study [J].Circulation,2020,141(9):728~739.
[9] 刁佳宇,赵宏谋,杨光,等.骨保护素是高血压患者冠脉钙化的独立危险因素并与血管紧张素Ⅱ相关[J].西安交通大学学报(医学版),2019,40(6):911~915.
[10] Rochette L,Meloux A,Rigal E,et al.The role of osteoprotegerin in vascular calcification and bone metabolism:the basis for developing new therapeutics [J].Calcif Tissue Int,2019,105(3):239~251.
[11] 华青,张敏芳,李璐瑶.骨特异性碱性磷酸酶在慢性肾脏病矿物质与骨代谢紊乱中的研究进展[J].中国中西医结合肾病杂志,2018,19(7):647~649.
[12] Donate-Correa J,Martin-Nunez E,Hernandez-Carballo C,et al.Fibroblast growth factor 23 expression in human calcified vascular tissues [J].Aging (Albany NY),2019,11(18):7899~7913. |
|
|
|
2021, Vol. 27 
